Sellas Life Sciences retail traders are largely refusing to cash out following a record H1 rally, with a Stocktwits poll showing 49% holding and 35% buying as the company's Phase 3 Regal trial in acute myeloid leukemia nears completion at 78 of 80 required events. SLS stock surged 292% in H1, surpassing its H1 2012 performance of 252%. Traders are focused on the final readout of the Regal trial testing GPS (galinpepimut-S) in AML, which requires 80 events to trigger final analysis. The rally comes as Sellas' market cap grew from $73 million at the start of 2024 to more than $1.5 billion by mid-2026, with recent corporate filings updating executive change-of-control arrangements.
Stocktwits Poll Shows 49% Holding SLS Stock Through Rally
In a Stocktwits poll asking users what they were doing with SLS stock, 49% said they were holding, and 35% said they were buying or adding to their positions. Only 8% said they were selling or trimming, while another 8% said they were watching from the sidelines. The poll has drawn about 2,700 votes. Sentiment on the platform is 'extremely bullish' amid 'extremely high' message volumes.
One Stocktwits user, citing a 760-share position, calculated what their stake could be worth at prices ranging from $20 to $150 and called the potential upside "life changing," adding that their "6th sense tells me July or August is the sweet spot." Another user pointed to Sellas' change-of-control filing, calling it the "ultimate corporate siren song to Big Pharma" players who may not yet have signed nondisclosure agreements. A third speculated that the trial's 80th event could be used in negotiations for a "premium BO price," saying that investors should "read the room" and "buy and hold." Another trader said that the day-to-day price action was "fun to watch" but "pretty irrelevant" as they were waiting for topline results or a buyout before selling any shares.
Regal Trial Reaches 78 of 80 Events for Final AML Analysis
The Phase 3 Regal trial of GPS (galinpepimut-S) in AML has reached 78 of the 80 events required to trigger its final analysis. Sellas CEO Angelos Stergiou has called the slower-than-expected accumulation of events an encouraging signal. "Crucially, the delay in reaching this 80th event is a profoundly positive signal---it suggests patients are living longer than projected," Stergiou said recently. "GPS has the potential to become the true standard of care in AML maintenance." Sellas has previously said that the Regal trial would be considered successful if GPS extends median overall survival to 12.6 months, compared with 8 months under standard treatment.
Investors are also watching SLS009, the company's Phase 2 CDK9 inhibitor for AML. Sellas expects topline data from its frontline AML trial later this year. SLS stock has rocketed 574% over the past year.
Sellas Updates Executive Severance and Change-of-Control Arrangements
Stergiou recently said Sellas' market cap has grown from $73 million at the start of 2024 to more than $1.5 billion by mid-2026. The company ended the first quarter with $107.1 million in cash and raised another $28.7 million through warrant exercises in April and May.
Sellas shareholders recently approved a 20 million-share increase to the company's 2023 Equity Incentive Plan. Stergiou was awarded 1.065 million restricted stock units vesting over four years, bringing his ownership to 1.76 million shares after the grant.
The company has updated executive severance and change-of-control arrangements. Stergiou's amended agreement shifts certain change-of-control severance payments to a lump sum, while CFO John Burns and Chief Development Officer Dragan Cicic would receive 15 months of base salary, target bonus payments, COBRA reimbursement and full equity acceleration under qualifying change-of-control terminations.
FAQ
What percentage of SLS retail traders are holding or buying stock?
A Stocktwits poll of about 2,700 voters shows 49% are holding SLS stock and 35% are buying or adding to their positions, with only 8% selling or trimming.
How close is Sellas' Regal trial to final analysis?
The Phase 3 Regal trial in AML has reached 78 of the 80 events required to trigger its final analysis. The trial tests GPS (galinpepimut-S) with a success threshold of extending median overall survival to 12.6 months compared with 8 months under standard treatment.
What corporate changes has Sellas made recently?
Sellas shareholders approved a 20 million-share increase to the 2023 Equity Incentive Plan, CEO Angelos Stergiou was awarded 1.065 million restricted stock units, and the company updated executive severance and change-of-control arrangements including lump-sum severance payments for Stergiou and 15-month packages for CFO John Burns and Chief Development Officer Dragan Cicic.
